

INDEX

- acceptability
 - Clinical Impression of Severity Index (CISI-PD), 19
 - scale attribute, 18–19, 24
- Addenbrooke's Cognitive Examination (ACE and revised ACE-R), cognitive screening, 198–199, 209
- administrative burden, 25–26
- AIMS (Abnormal Involuntary Movement Scale), dyskinesia, 84, 86–87, 96
- Alzheimer's disease, 165
- Alzheimer's Disease Assessment Scale–Cognition (ACAD–Cog), cognitive screening, 198, 199–200, 209
- American Quality of Well-Being Scale (QWB), cost utility, 158, 160, 163
- analysis of variance (ANOVA), 31
- anchor-based approaches, minimal clinically relevant change (MCRC), 43–44
- anhedonia
 - Chapman Scales for Physical and Social Anhedonia, 181–182
 - Parkinson's disease, 173–174
 - scales, 182–183
 - Snaith-Hamilton Pleasure Scale (SHAPS), 181
- anxiety disorders
 - assessment, 186–187
 - rating scales, 186, 187–188
- anxiety scales, 186, 187–188
 - Anxiety Status Inventory (ASI), 190
 - assessment, 191–192
 - Beck Anxiety Inventory (BAI), 188–189
 - Hamilton Anxiety Rating Scale (HARS), 190–191
 - Hospital Anxiety and Depression Scale–Anxiety Subscale (HADS–A), 189
 - Neuropsychiatric Inventory–Anxiety Subscale (NPI–A), 191
 - Self-Rating Anxiety Scale (SAS), 189–190
 - State Trait Anxiety Inventory (STAI), 190
- Anxiety Status Inventory (SAI), 188, 190, 192
- Apathy Evaluation Scale (AES), 175–176
- Apathy Inventory (AI), 175, 176, 177–178
- Apathy Scale (AS), 175, 176–177
 - apathy scales, 182
 - Apathy Evaluation Scale (AES), 175–176
 - Apathy Inventory (AI), 177–178
 - Apathy Scale (AS), 176–177
 - classification of scales, 176
 - Parkinson's disease, 173–174
- Assessment of Parkinson's Disease Scale (APDS), motor fluctuations, 101–103
- assessment of quality of life (AQOL)
 - cost utility, 156, 158, 159, 161
 - PD patients, 154
- assessment of scales
 - Classical Test Theory (CTT), 18–26
 - Rasch analysis, 26–34
- Autonomic Dysfunction in Parkinson's Disease, dysautonomia, 218, 224–225, 228
- Baylor Hallucinations Questionnaire, psychosis, 263, 264, 266–267
- Beck Anxiety Inventory (BAI), 188–189, 192

- Beck Depression Inventory (BDI), 286, 288, 290–291
- Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), psychosis, 263, 264, 269–270
- Belastungsfragebogen Parkinson Kurzversion (BELA-P-k), quality of life, 125, 130, 135
- “between-patients” score change, minimal clinically relevant change (MCRC), 44
- binary scaling, 8
- Bonferroni correction, 31
- Brief Psychiatric Rating Scale (BPRS), 174, 263, 264, 270–271
- Cambridge Cognitive Assessment (CAMCOG and CAMCOG-R), cognitive screening, 198, 200–201, 209
- ceiling effects, 9, 19
- Center for Epidemiologic Studies Depression Scale (CES-D), 286, 288, 295–296
- Chalder Fatigue Questionnaire (CFQ), 235, 236, 249–250
- change over time, measuring, 13–14
- Chapman Scales for Physical and Social Anhedonia, 175, 176, 181–182
- Classical Test Theory (CTT)
- assessment, 18–26
 - conceptual and measurement model, 18
 - feasibility and acceptability, 18–19
 - interpretability, 23, 25
 - item scaling, 18
 - psychometric attributes and criteria, 24
 - reliability, 19–20
 - respondent and administrative burdens, 25–26
 - responsiveness, 22–23
 - validation, 17–18
 - validity, 20–22
- clinical anchors, 44
- Clinical Dyskinesia Rating Scale (CDRS), 84, 86, 91–92, 96
- Clinical Global Impression–Improvement scale, 67
- Clinical Global Impression Scale (CGIS)
- fatigue, 235, 236, 251–252
 - psychosis, 263, 264, 275–276
- Clinical Global Impression–Severity (CGI-s), 78
- Clinical Impression of Severity Index (CISI-PD), 19
- Clinician Interview-based Impression of Change scale, 67
- clinimetrics
- Beck Depression Inventory (BDI), 290
 - Center for Epidemiologic Studies Depression Scale (CES-D), 296
 - Chalder Fatigue Questionnaire, 250
 - Clinical Global Impression Scale (CGIS), 252
 - Cornell Scale for Depression in Dementia (CSDD), 294
 - developments in, 54–55
 - Fatigue Assessment Inventory (FAI), 241–242
 - Fatigue Severity Inventory (FSI), 247–248
 - Fatigue Severity Scale (FSS), 239–240
 - Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT-F), 243
 - Geriatric Depression Scale (GDS), 293
 - Hamilton Depression Rating Scale (Ham-D), 287–288
 - Hoehn and Yahr (HY) scale, 118–119
 - Hospital Anxiety and Depression Scale (HADS), 291
 - Montgomery–Asberg Depression Rating Scale (MADRS), 289
 - Multidimensional Fatigue Inventory (MFI), 244–245
 - Parkinson Fatigue Scale (PFS), 246–247
 - Parkinson's Disease Sleep Scale (PDSS), 309
 - Pittsburgh Sleep Quality Index (PSQI), 310–311
 - SCOPA–Sleep, 312–313
 - Treatment Response Scale (TRS), 106–107
 - Unified Parkinson's Disease Rating Scale (UPDRS), 65–69
 - UPDRS, 295
 - Visual Analogue Scales (VAS), 251
 - Zung Self-Rating Depression Scale (SDS), 292
- cognitive impairment
- Parkinson's disease, 195–197
 - screening instruments, 197, 198
- cognitive impairment screening
- Addenbrooke's Cognitive Examination (ACE and revised ACE-R), 198–199
 - Cambridge Cognitive Assessment (CAMCOG and CAMCOG-R), 200–201
 - Dementia Rating Scale, 201–202
 - future perspective, 210
 - instruments, 198, 209, 210
 - Mini-Mental Parkinson (MMP), 202–203
 - Mini-Mental State Examination (MMSE), 203
 - Montreal Cognitive Assessment (MOCA), 204–205
 - Parkinson Neuropsychometric Dementia Assessment (PANDA), 206–207
 - Parkinson's Disease Cognitive Rating Scale (PD-CRS), 205–206
 - Parkinson's Disease Dementia–Short Screen (PDD-SS), 206
 - Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 207–208
 - Scales for Outcomes of Parkinson's Disease–Cognition (SCOPA-COG), 208, 210
- cognitive pretesting, 11
- Cohen's Kappa correlations, 12
- Columbia University Rating Scale (CURS), 52, 100
- common factor model, 12
- comorbidities
- Chalder Fatigue Questionnaire, 249
 - Fatigue Assessment Inventory (FAI), 241
 - Fatigue Impact Scale for Daily Use (D-FIS), 248
 - Fatigue Severity Inventory (FSI), 247
 - Fatigue Severity Scale (FSS), 239
 - Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT-F), 242
 - Hoehn and Yahr (HY) scale, 116–117
 - MDS–UPDRS, 76
 - Multidimensional Fatigue Inventory (MFI), 244
 - Parkinson Fatigue Scale (PFS), 246
 - Parkinson's Disease Sleep Scale (PDSS), 308
 - Pittsburgh Sleep Quality Index (PSQI), 310
 - SCOPA-sleep scale, 312
 - Unified Parkinson's Disease Rating Scale (UPDRS), 63–64
- COMPASS (Composite Autonomic Symptom Scale), dysautonomia, 218, 220, 228
- Confirmative Fit Index (CFI), 13
- confirmatory factor analysis, 13
- Consensus-based Standard for selection of health status Measurement Instruments (COSMIN) panel, 21, 135
- construct validity, 21
- content evidence, 11
- content validity, 20, 24
- content validity ratio (CVR), 6
- convergent validity, 21–22
- Core Assessment Programs for Intracerebral Transplantation and Surgical Interventional Therapies for PD (CAPIT/CAPSIT), 65
- Core Assessment Programs for Surgical Interventional Therapies in PD (CAPSIT-PD)
- diary, 99, 101, 107, 110–111
- Cornell Scale for Depression in Dementia (CSDD), 286, 288, 293–294
- Cost-effectiveness (CE), 146, 149

- cost of illness (COI), 145, 164
 - assessment in patients with Parkinson's disease, 146, 149
 - resource components, 150–151
 - studies in PD, 147–148
- cost utility (CU), 146
 - 15D, 157, 158, 160, 163
 - assessment of quality of life (AQOL), 156, 158, 159, 161
 - direct and indirect measurements of preference-based outcomes, 149, 152
 - direct utility assessment, 152
 - EQ-5D, 157, 159, 161
 - evaluating PD patient preferences, 153–154
 - Health Utility Index (HUI), 157, 158, 159, 161–162
 - Index of Health Related Quality of Life (IHQL), 162
 - indirect utility assessment, 152
 - preference-based outcomes, 164–165
 - Quality of Well-Being Scale (QWB), 158, 160, 163
 - Rosser disability/distress scale, 158, 160, 162
 - scales, 152–164
 - SF-60, 157, 162–163
 - standard gamble (SG), 152
 - time trade-off (TTO), 156
 - utility measurements in PD patients, 155
 - visual analogue scale (VAS), 156
- criterion validity, 20–21, 24
- Cronbach's alpha, 12, 20, 29
- cross-cultural validity, 22

- Delphi approach, 5, 6
- Dementia, psychosis scales, 268–270
- Dementia Rating Scale, cognitive screening, 198, 201–202, 209
- depression rating scales, 286, 288
 - Beck Depression Inventory (BDI), 290–291
 - Center for Epidemiologic Studies Depression Scale (CES-D), 295–296
 - clinical practice and research, 285–287
 - Cornell Scale for Depression in Dementia (CSDD), 293–294
 - depression in Parkinson's disease (dPD), 284
 - Geriatric Depression Scale (GDS), 292–293
 - Hamilton Depression Rating Scale (Ham-D), 287–289
 - Hospital Anxiety and Depression Scale (HADS), 291–292
 - literature search strategy, 284
 - methods, 284
 - Montgomery–Asberg Depression Rating Scale (MADRS), 289
 - problems when using for dPD, 284–285
 - recommendations, 296–299
 - Unified Parkinson's Disease Rating Scale (UPDRS) Part I, 295
 - Zung Self-Rating Depression Scale (SDS), 292
- Diagnostic and Statistical Manual, 4th edition, Text Revision* (DSM-IV-TR), 186, 187, 237–238, 261
- differential item functioning (DIF), 14, 31, 33
- disabilities, 52
- disablement process, 52, 53
- disease models, developments in, 52–54
- distribution approaches, minimal clinically relevant change (MCRC), 44–45
- divergent validity, 21–22
- domain and scaling, relationship, 7
- domain of interest, 5
- dysautonomia rating scales
 - Autonomic Dysfunction in Parkinson's Disease, 224–225
 - Autonomic Scale for Outcomes in Parkinson's disease (SCOPA-AUT), 217, 219
 - clinical perspectives, 228–229
 - COMPASS (Composite Autonomic Symptom Scale), 220
 - Freiburg Questionnaire, 224
 - Hobson Scale, 226
 - L-threo DOPS Evaluation Scale, 226
 - methods, 216
 - Non-Motor Symptoms Questionnaire for Parkinson's disease (NMS Quest), 220–221
 - Non-Motor Symptoms Scale (NMSS), 221–223
 - Orthostatic Grading Scale (OGS), 225–226
 - orthostatic hypotension, 215–216
 - scale characteristics, 227
 - scales and questionnaires, 216–217, 218, 228, 229
 - Senard *et al.* 1997, 226
 - UPDRS and MDS–UPDRS, 223–224
- dyskinesia, drug-induced, in PD, 84–85
- dyskinesia scales
 - AIMS (Abnormal Involuntary Movement Scale), 86–87
 - Clinical Dyskinesia Rating Scale (CDRS), 91–92
 - Lang–Fahn Activities of Daily Living Dyskinesia Scale, 92–93
 - MDS–UPDRS, 88–89
 - Obeso Dyskinesia Rating Scale (CAPIT), 89–90
 - Parkinson Disease Dyskinesia Scale (PDYS–26), 93–94
 - recommendations, 95–96
 - Rush dyskinesia scale, 90–91
 - Unified Dyskinesia Rating Scale (UDysRS), 94–95
 - UPDRS, 87–88
- effect size, 45
- Epworth Sleepiness Scale, 26
- equivalent forms reliability, 20
- Essay on the Shaking Palsy*, Parkinson, 55
- EUROQOL 5-Dimensions (EQ-5D)
 - cost utility, 159, 161
 - health-related quality of life, 125, 126–127, 135
 - patients with PD, 153
- experts, domains of interest, 5–6

- face validity, 20
- factor analysis, 12–13
- factor identification, 13
- Fast Force for Parkinson's Disease Rating Scales, Movement Disorder Society, 14
- Fatigue Assessment Inventory (FAI), 235, 236, 240–242
- Fatigue Impact Scale for Daily Use (D-FIS), 235, 236, 248–249
- fatigue rating scales
 - Chalder Fatigue Questionnaire (CFQ), 249–250
 - characteristics, 235
 - Clinical Global Impression Scale (CGIS), 251–252
 - confounds associated with applying, 237
 - Fatigue Assessment Inventory (FAI), 240–242
 - Fatigue Impact Scale for Daily Use (D-FIS), 248–249
 - Fatigue Severity Inventory (FSI), 247–248
 - Fatigue Severity Scale (FSS), 238–240
 - Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT-F), 242–244
 - identified scales, 234, 235, 236
 - inconsistent definitions, 237
 - measures in PD, 236
 - methods, 234
 - Multidimensional Fatigue Inventory (MFI), 244–245
 - overlap of fatigue with neuropsychiatric disturbances, 237–238
 - Parkinson Fatigue Scale (PFS), 245–247
 - recommendations, 252–253
 - unidimensional vs. multidimensional scales, 238
 - Visual Analogue Scales (VAS), 250–251
- Fatigue Severity Inventory (FSI), 235, 236, 247–248
- Fatigue Severity Scale (FSS), 26, 235, 236, 238–240
- feasibility, scale attribute, 18–19, 24
- Feinstein, Alvan, 54
- floor effects, 9, 19

- focus group, 5, 6
- Food and Drug Administration (FDA), 10
- Fragebogen Parkinson Lebensqualität (PLQ), 125, 133, 135
- Freiburg Questionnaire, dysautonomia, 218, 224, 228
- Frontal Systems Behavior Scale (FSBS), 174
- F-statistic, 23
- Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT–F), 26, 235, 236, 242–244
- Geriatric Depression Scale (GDS), 286, 288, 292–293
- Hamilton Anxiety Rating Scale (HARS), 188, 190–191, 192
- Hamilton Depression Rating Scale (Ham–D), 286, 287–289
- handicaps, 52
- Hauser Parkinson's Disease Diary, motor fluctuations, 99, 101, 107, 110–111
- health, concept, 164
- health economic studies. *See also* cost utility (CU)
- comparative studies, 145–146
 - noncomparative studies, 145
- health-related quality of life (HRQOL) scales, 44
- Belastungsfragebogen Parkinson Kurzversion (BELA–P–k), 130
 - EUROQOL 5-Dimensions (EQ–5D), 126–127
 - Fragebogen Parkinson Lebensqualität (PLQ), 133
 - key evaluation points, 135
 - literature search strategy, 124–125
 - Medical Outcomes Study 36-Item Short–Form Health Survey (SF–36), 127–128
 - methods, 124–125
 - Nottingham Health Profile (NHP), 126
 - Parkinson's Disease Quality of Life Questionnaire (PDQL), 132
 - Parkinson's Disease Quality of Life Scale (PDQUALIF), 132–133
 - Parkinson's Disease Questionnaire (PDQ–39), 130–131
 - Parkinson's Disease Questionnaire Short Form (PDQ–8), 131
 - Parkinson's Impact Scale (PIMS), 131–132
 - Parkinson's Problem Schedule (PPS), 133–134
 - Quality of Life Questionnaire 15D (15D), 128–129
 - Questions on Life Satisfaction–Deep Brain Stimulation (QLS–DBS) module, 129–130
 - Questions on Life Satisfaction–Movement Disorders (QLS–MD) module, 129–130
 - recommendations, 134–137
 - Scales for Outcomes in Parkinson's Disease–Psychosocial (SCOPA–PS), 134
 - Schedule for the Evaluation of Individual Quality of Life–Direct Weighting (SEIQOL–DW), 128
 - Sickness Impact Profile (SIP), 125–126
 - WHO Quality of Life Assessment Short Version (WHOQOL–BREF), 129
- health status (HS), 124
- Health Utility Index (HUI)
- cost utility, 157, 158, 159, 161–162
 - patients with PD, 154
- Hobson scale, dysautonomia, 218, 226, 228
- Hoehn and Yahr scale, 52, 115, 116
- clinimetric issues, 118
 - comparing original and modified, 116
 - future, 120
 - handling comorbidities, 116–117
 - key evaluation issues, 117–119
 - MCRD, 119
 - MCRID, 119
 - reliability, 118
 - responsiveness, 119
 - scale description, 116–117
 - strengths and weaknesses, 119–120
 - structure, 116
 - use by multiple authors, 118
 - use in PD and across disease spectrum, 117–118
 - validity, 118–119
- Hospital Anxiety and Depression Scale (HADS), 26, 286, 288, 291–292
- Hospital Anxiety and Depression Scale–Anxiety Subscale (HADS–A), 188, 189, 192
- hypothesis testing validity, 24
- IMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials), 56
- Impact on Participation and Autonomy questionnaire, 26
- impairments, 52
- Index of Health Related Quality of Life (IHQL), cost utility, 162
- insomnia, sleep disturbances, 307–308
- Intermediate Scale for Assessment of PD (ISAPD), motor fluctuations, 100, 102, 103
- internal consistency, 9, 12, 19–20, 24
- internal validity, 22, 23
- International Classification of Functioning, Disability and Health (ICF), 52, 53
- International Classification of Impairments, Disabilities and Handicaps (ICIDH), 52–53
- interpretability, classical test theory (CTT), 23, 25
- inter-rater reliability, 11–12
- intra-class correlations, 12
- Item Response Theory (IRT), 14, 17–18
- item scaling, SCOPA–sleep scale, 19
- Kappa correlations, 12
- Known-groups validity, 22
- Kruskal–Wallis test, 22, 23
- Kuder–Richardson formula 20 (KR 20), 20
- Lang–Fahn Activities of Daily Living Dyskinesia Scale, dyskinesia, 84, 86, 92–93, 96
- Latent Trait Theories, 17–18
- Likert rating, 8–9
- Likert scales, 7, 8, 190
- Lille Apathy Rating Scale (LARS), 174, 175, 176, 178–179
- Lin's concordance coefficient (LCC), 12, 20
- literature search
- cognitive screening instruments, 198
 - depression, 284
 - health-related quality of life, 124–125
- local independence, 30–31
- L-three DOPS Evaluation Scale, dysautonomia, 218, 226, 228
- Mattis Dementia Rating Scale (MDRS), cognitive screening, 198, 201–202, 209
- Medical Outcomes Study 36-Item Short–Form Health Survey (SF–36)
- cost utility, 158, 160, 162–163
 - health-related quality of life, 125, 127–128, 135
- mental fatigue, 237
- minimal clinically important change (MCIC), UPDRS, 66–67
- minimal clinically important difference (MCID), 25, 43
- minimal clinically relevant change (MCRC), 42
- anchor-based approaches, 43–44
 - distribution-based approaches, 44–45
 - effect size and standard deviation, 45
 - methods to calculate, 43–45
 - standard error of measurement (SEM), 45
 - uses of, 45–46

- minimal clinically relevant difference (MCDR), 42
 - Hoehn and Yahr (HY) scale, 119
 - MDS–UPDRS, 78–79
 - UPDRS, 66–68
- minimal clinically relevant incremental difference (MCRID)
 - Hoehn and Yahr (HY) scale, 119
 - MDS–UPDRS, 78–79
 - UPDRS, 66, 68
- minimal important change (MIC), 25
- Mini-Mental Parkinson (MMP), cognitive screening, 198, 202–203, 209
- Mini-Mental State Examination (MMSE), cognitive screening, 198, 203, 209
- missing data, 19
- Montgomery–Asberg Depression Rating Scale (MADRS), 286, 288, 289
- Montreal Cognitive Assessment (MOCA), cognitive screening, 198, 204–205, 209
- motor fluctuations, 99–100
 - Assessment of Parkinson’s Disease Scale (APDS), 101–103
 - CAPSIT–PD diary, 110–111
 - future perspectives, 111–112
 - Hauser Parkinson’s Disease Diary, 110–111
 - Intermediate Scale for Assessment of PD (ISAPD), 103
 - MDS–UPDRS, 105–106
 - methodology, 101
 - questionnaires for, detection, 107–109
 - SCOPA–Motor Scale (S–MS), 104–105
 - self evaluation diaries, 109–111
 - Treatment Response Scale (TRS), 106–107
 - UPDRS, 103–104
 - Wearing-Off Questionnaire (WOQ), 108–109
- Movement Disorders*, 60, 146, 260
- Movement Disorder Society (MDS)
 - anxiety scales, 187–188
 - dyskinesia scales, 84, 96
 - future developments, 56
 - health-related quality of life, 124
 - methodology for rating scale review, 59–60
 - outcome of rating scales review, 60–61
 - Task Force for Parkinson’s Disease Rating Scales, 14
- Movement Disorder Society Unified Parkinson’s Disease Scale (MDS–UPDRS), 11, 13, 14, 60
 - clinimetric issues, 76–79
 - conceptual mapping of items and scores, 72–75
 - covered items, 71
 - dysautonomia, 218, 223–224, 228
 - dyskinesia, 84, 86, 88–89, 96
 - evaluation issues, 76–79
 - final assessment, 79
 - future, 79–80
 - handling comorbidities, 76
 - MCRD and MCRID, 78–79
 - motor fluctuations, 101, 102, 105–106
 - ratings, 70
 - reliability, 77
 - responsiveness, 78
 - scale description, 70–72, 76
 - strengths and weaknesses, 79
 - structure, 70–72
 - use by multiple authors, 76
 - use in PD and across disease spectrum, 76
 - validity, 77–78
- M-Plus, 14
- Multidimensional Fatigue Inventory (MFI), 235, 236, 244–245
- multiple cause structural equation models (MIMIC), 14
- National Institute of Neurological Disorders and Stroke (NINDS), 61
- neuropsychiatric disturbances, fatigue and, 237–238
- Neuropsychiatric Inventory (NPI), 174
 - item 7 (apathy), 175, 176, 179–180
 - psychosis, 263, 264, 268–269
- Neuropsychiatric Inventory–Anxiety Subscale (NPI–A), 188, 191, 192
- New York University Rating Scale (NYURS), 52
- nocturnal sleep scales, 314, 315
 - Parkinson’s Disease Sleep Scale (PDSS and PDSS–2), 308–310
 - Pittsburgh Sleep Quality Index (PSQI), 310–312
 - SCOPA–SLEEP, 312–313
- Non-Motor Symptoms Questionnaire for Parkinson’s Disease (NMS Quest), dysautonomia, 218, 220–221, 229
- Non-Motor Symptoms Scale (NMSS), dysautonomia, 218, 221–223, 228
- Northwestern University Disability Scale (NUDS), 52, 100
- Nottingham Health Profile (NHP), 26, 125, 126, 135
- Nurses’ Observation Scale for Inpatient Evaluation (NOSIE–30), psychosis, 263, 264, 274–275
- Obeso Dyskinesia Rating Scale (CAPIT), dyskinesia, 84, 86, 89–90, 96
- OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials), 56
- Orthostatic Grading Scale (OGS), dysautonomia, 218, 225–226, 228
- orthostatic hypotension. *See also* dysautonomia rating scales
 - definition and assessment, 216
 - prevalence, 215–216
 - scales and questionnaires, 216–217, 218
- Parkinson, James, 55
- Parkinson Disease Dyskinesia Scale (PDYS–26), 26, 84, 86, 93–94, 96
- Parkinson Fatigue Scale (PFS), 235, 236, 245–247
- Parkinson Neuropsychometric Dementia Assessment (PANDA), cognitive screening, 198, 206–207, 209
- Parkinson Psychosis Questionnaire (PPQ), 263, 264, 265
- Parkinson Psychosis Rating Scale (PPRS), 262–265
- Parkinson’s disease (PD), 5
 - anxiety disorders, 186–187
 - cost-of-illness assessment, 146–149
 - developments in clinical view, 55–56
 - drug-induced dyskinesia, 84–85
 - history of rating scales, 51–52
 - term, 125
 - Unified Parkinson’s Disease Rating Scale (UPDRS), 63–70
- Parkinson’s Disease Cognitive Rating Scale (PD–CRS), 198, 205–206, 209
- Parkinson’s Disease Dementia–Short Screen (PDD–SS), cognitive screening, 198, 206, 209
- Parkinson’s Disease Impairment Scale, 100
- Parkinson’s Disease Quality of Life Questionnaire (PDQL), 125, 132, 135
- Parkinson’s Disease Quality of Life Scale (PDQUALIF), 125, 132–133, 135
- Parkinson’s Disease Questionnaire (PDQ–39), quality of life, 125, 130–131, 135
- Parkinson’s Disease Questionnaire Short Form (PDQ–8), quality of life, 125, 131, 135
- Parkinson’s Disease Sleep Scale (PDSS and PDSS–2), 308–310, 314, 315
- Parkinson’s Impact Scale (PIMS), quality of life, 125, 131–132, 135
- Parkinson’s Problem Schedule (PPS), 125, 133–134, 135
- Pearson’s coefficients, 11

- person-item distribution graph, 33, 34
 Person Separation Index (PSI), 29
 Phi coefficients, 11
 physical fatigue, 237
 Pittsburgh Sleep Quality Index (PSQI), 310–312, 314, 315
 Positive and Negative Syndrome Scale (PANSS), psychosis, 263, 264, 271–273
 precision, 22
 principal component analysis, Rasch, 31, 32
 Profile of Moods States Questionnaire (POMS), 174
 psychometric attributes
 Fatigue Impact Scale for Daily Use (D-FIS), 248–249
 scale, 18, 24
 psychometry, 54
 psychosis rating scales
 Baylor Hallucinations Questionnaire, 266–267
 Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), 269–270
 Brief Psychiatric Rating Scale (BPRS), 270–271
 Clinical Global Impression Scale (CGIS), 275–276
 dementia, 268–270
 Neuropsychiatric Inventory (NPI), 268–269
 Nurses' Observation Scale for Inpatient Evaluation (NOSIE-30), 274–275
 occurrence in Parkinson's disease (PD), 260–262
 Parkinson Psychosis Questionnaire (PPQ), 265
 Parkinson Psychosis Rating Scale (PPRS), 262, 264–265
 Parkinson's disease, 262–268, 275–277
 Positive and Negative Syndrome Scale (PANSS), 271–273
 proposed diagnostic criteria, 261
 recommendations, 277–278
 Rush Hallucination Inventory, 265–266
 Schedule for Assessment of Positive Symptoms (SAPS), 273–274
 schizophrenia, 270–275
 University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ), 267–268
 UPDRS, 276–277
 quality-adjusted life-years (QALYs), 152
 Quality of Life Questionnaire 15D (15D)
 cost utility, 157, 158, 160, 163
 health-related quality of life, 125, 128–129, 135
 patients with PD, 153
 quality of life scale. *See* health-related quality of life (HRQOL) scales
 Quality of Well-Being Scale (QWB)
 cost utility, 158, 160, 163
 patients with PD, 153
 questionnaires. *See also* health-related quality of life (HRQOL) scales; Wearing-Off Questionnaire (WOQ)
 motor fluctuations, 99, 101, 107–109
 Questions on Life Satisfaction–Deep Brain Stimulation (QLO-DBS) Module, 125, 129–130, 135
 Questions on Life Satisfaction–Movement Disorders (QLO-MD) Module, 125, 129–130, 135
 Rasch analysis, 18
 assessment, 26–34
 checklist, 36
 choosing version of, 27
 differential item functioning (DIF), 31
 fit to Rasch model, 27
 local independence, 30–31
 raw sumscores to linear measure, 33–34, 35
 reliability, 28–29
 sample size, 28, 29
 scale targeting, 31, 33
 threshold ordering, 29–30
 unidimensionality, 31, 32
 Rasch Unidimensional Measurement Models, 27
 rating scales
 classification, 60
 error, 4–5
 history in Parkinson's disease, 51–52
 process of developing, 4, 5–9
 purpose, 3–4
 refinement, 9
 reliability, 10, 54
 classical test theory (CTT), 19–20
 Hoehn and Yahr (HY) scale, 118
 MDS-UPDRS, 77
 Rasch analysis, 28–29
 scale development, 11–12
 UPDRS, 65–66
 Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), cognitive screening, 198, 207–208, 209
 reproducibility, scale attribute, 24
 Resource Utilization Instrument for Dementia (RUD), 164, 165
 respondent burden, 25–26
 responsiveness, 54
 classical test theory (CTT), 22–23, 24
 Hoehn and Yahr (HY) scale, 119
 MDS-UPDRS, 78
 UPDRS, 66
 Ribot, Théodule, 174
 Root-mean-square error (RMSE), 13
 Rosser disability/distress scale
 cost utility, 158, 160, 162
 patients with PD, 154
 Rush Dyskinesia Rating Scale, dyskinesia, 84, 86, 90–91, 96
 Rush Hallucination Inventory, 263, 264, 265–266
 scale targeting, 31, 33
 scatter plot, 21
 Schedule for Assessment of Positive Symptoms (SAPS), psychosis, 263, 264, 273–274
 Schedule for the Evaluation of Individual Quality of Life–Direct Weighting (SEIQOL-DW), health-related quality of life, 125, 128, 135
 schizophrenia, psychosis scales, 270–275
 Schwab and England scale, 52, 67
 SCOPA-AUT (Autonomic Scale for Outcomes in Parkinson's disease), 26
 dysautonomia, 217, 218, 219, 228
 SCOPA-COG (Scales for Outcomes of Parkinson's Disease–Cognition), 26, 27
 cognitive screening, 198, 208, 209, 210
 SCOPA-Motor Scale (S-MS), motor fluctuations, 101, 102, 104–105
 SCOPA-PS (Scales for Outcomes in Parkinson's Disease–Psychosocial), 27
 category probability curve, 30
 differential item functioning (DIF), 33
 global fit to Rasch model, 28
 individual item fit, 29
 person-item residual correlation, 31
 principal component analysis, 32
 quality of life, 125, 134, 135
 Rasch analysis, 28–35
 raw sumscores to linear measure, 35
 reliability, 29
 sample size and descriptives, 29
 threshold ordering, 28
 t-test values, 32
 SCOPA-sleep scale, 19, 312–313, 314, 315

- self-evaluation diaries, motor fluctuations, 99, 101, 109–111
- Self-Rating Anxiety Scale (SAS), 188, 189–190, 192
- Self-Rating Depression Scale (SDS), 286, 288, 292
- Senard et al. 1997, dysautonomia, 218, 226, 229
- sensitivity-based approach, minimal clinically relevant change (MCRC), 44
- severity, domain and scaling, 7
- SF-36. *See* Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36)
- Short Parkinson's Evaluation Scale (SPES), 104
- Sickness Impact Profile (SIP), health-related quality of life, 125–126, 135
- sleep disturbances. *See also* nocturnal sleep scales
Parkinson's disease, 307–308
- sleep scale, 10
- Snaith-Hamilton Pleasure Scale (SHAPS), 175, 176, 181
- social comparison approach, MCRC, 44
- sociometry, 54
- Spearman's coefficients, 11
- specificity-based approach, minimal clinically relevant change (MCRC), 44
- Stacy questionnaire, WOQ-32, 100, 101, 107–109
- standard deviation, 45
- standard error of measurement (SEM), 22, 45
- standard error variance (SEM), 22
- standard gamble (SG), cost utility (CU), 152
- State Trait Anxiety Inventory (STAI), 188, 190, 192
- statistics
cognitive pretesting, 11
content evidence, 11
differential item functioning (DIF), 14
factor analysis, 12–13
future, 14
internal consistency, 12
measuring change over time, 13–14
reliability, 11–12
subgroup differentiation, 13–14
- subgroup differentiation, 13–14
- summary indexes, 21
- tariffs, 161
- test–retest reliability, 11
- Tests in Print*, 5
- time trade-off (TTO), cost utility, 156
- Treatment Response Scale (TRS), motor fluctuations, 101, 102, 106–107
- t*-tests, 23, 32
- Unified Dyskinesia Rating Scale (UDysRS), dyskinesia, 84, 86, 94–95, 96
- Unified Parkinson's Disease Rating Scale (UPDRS), 13, 52, 53, 59
clinimetric issues, 65–69
- conceptual mapping of items and scores, 72–75
- depression, 286, 288, 295
- dysautonomia, 218, 223–224, 229
- dyskinesia, 84, 86, 87–88, 96
- evaluation issues, 64–69
- final assessment, 69–70
- handling comorbidities, 63–64
- internal validity, 23
- item 4 (motivation/initiative), 174, 175, 176, 179
- MCRD, MCIC and MCRID, 66–68
- motor fluctuations, 101, 103–104
- Movement Disorder Society (MDS) revision, 14, 60
- psychosis, 263, 264, 276–277
- ratings, 70
- reliability, 65–66
- responsiveness, 66
- scale description, 63–64
- strengths and weaknesses, 68–69
- structure, 63
- use by multiple authors, 65
- use in PD and across disease spectrum, 64–65
- validity, 66
- University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ), 263, 264, 267–268
- validation, scale, 17–18
- validity, 10, 54
classical test theory (CTT), 20–22
Hoehn and Yahr (HY) scale, 118–119
MDS–UPDRS, 77–78
UPDRS, 66
- Visual Analogue Scale (VAS)
cost utility, 156
fatigue, 235, 236, 250–251
patients with PD, 153
- Wearing-Off Questionnaire (WOQ)
motor fluctuations, 99, 101, 108–109
QQ-WOQ, 101, 107, 108
WOQ-19, 100, 101, 108–109
WOQ-32, 100, 101, 107, 108–109
WOQ-9, 100, 101, 107, 108–109
- Webster scale, 52
- WHO Quality of Life Assessment Short Version (WHOQOL-BREF), health-related quality of life, 125, 129, 135
- “within-patients” score change, minimal clinically relevant change (MCRC), 44
- World Health Organization (WHO), 124
- Zung Self-Rating Anxiety Scale (SAS), 188, 189–190, 192
- Zung Self-Rating Depression Scale (SDS), 286, 288, 292
- z*-values, 23